Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Interventional Glaucoma Consortium (IGC) is a professional organization and collaborative group of leading ophthalmologists dedicated to advancing the 'interventional glaucoma' paradigm. This approach emphasizes early surgical or procedural intervention—such as Minimally Invasive Glaucoma Surgery (MIGS) and advanced laser therapies—over traditional long-term topical medication. The consortium focuses on clinical education, establishing treatment algorithms, and promoting innovation in glaucoma management to improve patient outcomes and quality of life. By shifting the focus from reactive to proactive care, the IGC aims to address issues like patient non-compliance and the ocular surface disease associated with chronic drop use. The group provides a platform for specialists to share data, refine surgical techniques, and collaborate with industry partners on next-generation ophthalmic technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Interventional Glaucoma Consortium.